Related Experiment Video
Updated: Jan 31, 2026

Self-reporting Scaffolds for 3-Dimensional Cell Culture
Published on: November 7, 2013
BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases
Eugene Liat Hui Ong1, Rishika Sinha2, Shilan Jmor3
1Dermatology Department, Chelsea Westminster Hospital, London, United Kingdom.
Abstract:
Cutaneous toxicities associated with BRAF inhibitor treatment in patients with metastatic melanoma have been well described. We present a rare association of granulomatous dermatitis in association with the BRAF inhibitor vemurafenib. Three patients with metastatic melanoma all presented with asymptomatic papular eruptions 8-21 months into vemurafenib therapy. Skin biopsies confirmed the diagnosis of granulomatous dermatitis. Other causes of granulomatous dermatitis including infectious agents and sarcoid were excluded. Treatment with potent topical and oral steroids improved the eruptions, but only after the cessation of vemurafenib did all 3 cases of granulomatous dermatitis completely resolve within 2 weeks. It is important to recognize that this association, unlike most other BRAF inhibitor-related skin toxicities, can occur many months after commencement of therapy and that vemurafenib treatment can be continued without clinically significant adverse effects.
Insights
Granulomatous dermatitis is a rare side effect of vemurafenib, a BRAF inhibitor used for metastatic melanoma. This skin condition resolved quickly after stopping vemurafenib treatment.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- BRAF inhibitors are a targeted therapy for metastatic melanoma.
- Cutaneous toxicities are common with BRAF inhibitor treatment.
- Granulomatous dermatitis is a rare but distinct adverse reaction.
Observation:
- Three patients with metastatic melanoma developed asymptomatic papular eruptions.
- The eruptions appeared 8-21 months after initiating vemurafenib therapy.
- Skin biopsies confirmed granulomatous dermatitis, excluding other causes.
Findings:
- Granulomatous dermatitis associated with vemurafenib can occur late in treatment.
- Topical and oral steroids provided partial improvement.
- Complete resolution of skin lesions occurred within two weeks of discontinuing vemurafenib.
Implications:
- Clinicians should consider granulomatous dermatitis in patients on long-term vemurafenib.
- This specific toxicity may allow for continued BRAF inhibitor therapy after resolution.
- Early recognition and management can improve patient quality of life during melanoma treatment.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Types of Reports III: Telephone and Verbal Reports
Here's an overview of each type:
Telephone Orders
Reporter Genes

